intervention as well as psychotherapy would be indicated (Armstrong, 2011). The provider’s approach to GF’s assessment should be cautious as she is making a big step to seek help. The providers should ask the above questions in a way which is non- judgmental and in a comfortable setting for the patient. Due to the combination of anxiety and depression, a serotonin norepinephrine reuptake inhibitor would be indicated (Ballenger, 2000). To control GF anxiety effectively, venlafaxine immediate release at 37.5 mg PO daily would be most appropriate for the acute phase of treatment (Armstrong, 2011). This dose would need to be titrated accordingly after close monitoring of GF for efficacy of treatment and minimal side effects. GF will also be referred for psychotherapy for optimal treatment (Armstrong, 2011). Education with GF would include both information about venlafaxine, as well as important lifestyle changes. Adverse effects of venlafaxine include hypertension, dizziness, nausea or vomiting, sleep disturbances or increased diaphoresis (American Psychiatric Association, 2010). To ensure adherence to the treatment plan, it is imperative to involve GF in
WEEK 5 ASSIGNMENT 1 3 the medication selection process and discuss her feelings about taking an antidepressant. Discuss psychotherapy and GF’s willingness to participate in psychotherapy. Try to address possible stigmas GF may have associated with psychotherapy, her ability to get to her appointments and the effect that will have on her routine and lifestyle.
You've reached the end of your free preview.
Want to read all 4 pages?
- Fall '16
- Psychiatry, Selective serotonin reuptake inhibitor, Major depressive disorder, Norepinephrine reuptake inhibitor, Venlafaxine